These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 17177381)

  • 41. Purification and characterization of an O-GlcNAc selective N-acetyl-beta-D-glucosaminidase from rat spleen cytosol.
    Dong DL; Hart GW
    J Biol Chem; 1994 Jul; 269(30):19321-30. PubMed ID: 8034696
    [TBL] [Abstract][Full Text] [Related]  

  • 42. O-GlcNAc transferase inhibitors: current tools and future challenges.
    Trapannone R; Rafie K; van Aalten DM
    Biochem Soc Trans; 2016 Feb; 44(1):88-93. PubMed ID: 26862193
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Evidence of a compensatory regulation of colonic O-GlcNAc transferase and O-GlcNAcase expression in response to disruption of O-GlcNAc homeostasis.
    Decourcelle A; Loison I; Baldini S; Leprince D; Dehennaut V
    Biochem Biophys Res Commun; 2020 Jan; 521(1):125-130. PubMed ID: 31630803
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Chemical dissection of the link between streptozotocin, O-GlcNAc, and pancreatic cell death.
    Pathak S; Dorfmueller HC; Borodkin VS; van Aalten DM
    Chem Biol; 2008 Aug; 15(8):799-807. PubMed ID: 18721751
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Functional significance of O-GlcNAc modification in regulating neuronal properties.
    Hwang H; Rhim H
    Pharmacol Res; 2018 Mar; 129():295-307. PubMed ID: 29223644
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Diazaspirononane Nonsaccharide Inhibitors of O-GlcNAcase (OGA) for the Treatment of Neurodegenerative Disorders.
    Martínez-Viturro CM; Trabanco AA; Royes J; Fernández E; Tresadern G; Vega JA; Del Cerro A; Delgado F; García Molina A; Tovar F; Shaffer P; Ebneth A; Bretteville A; Mertens L; Somers M; Alonso JM; Bartolomé-Nebreda JM
    J Med Chem; 2020 Nov; 63(22):14017-14044. PubMed ID: 33197187
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Alloxan is an inhibitor of O-GlcNAc-selective N-acetyl-beta-D-glucosaminidase.
    Lee TN; Alborn WE; Knierman MD; Konrad RJ
    Biochem Biophys Res Commun; 2006 Dec; 350(4):1038-43. PubMed ID: 17045574
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Structural insights into mechanism and specificity of O-GlcNAc transferase.
    Clarke AJ; Hurtado-Guerrero R; Pathak S; Schüttelkopf AW; Borodkin V; Shepherd SM; Ibrahim AF; van Aalten DM
    EMBO J; 2008 Oct; 27(20):2780-8. PubMed ID: 18818698
    [TBL] [Abstract][Full Text] [Related]  

  • 49. OGA Inhibition Alters Energetics and Nutrient Sensing in Alzheimer's Disease Cytoplasmic Hybrids.
    Flax J; Wilkins HM; Miller R; Griffith S; Cork GK; Qiang A; Thompson J; Swerdlow RH; Slawson C
    J Alzheimers Dis; 2020; 78(4):1743-1753. PubMed ID: 33285636
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Inhibition of O-GlcNAcase by a gluco-configured nagstatin and a PUGNAc-imidazole hybrid inhibitor.
    Shanmugasundaram B; Debowski AW; Dennis RJ; Davies GJ; Vocadlo DJ; Vasella A
    Chem Commun (Camb); 2006 Nov; (42):4372-4. PubMed ID: 17057847
    [TBL] [Abstract][Full Text] [Related]  

  • 51. O-GlcNAcase deficiency suppresses skeletal myogenesis and insulin sensitivity in mice through the modulation of mitochondrial homeostasis.
    Wang X; Feng Z; Wang X; Yang L; Han S; Cao K; Xu J; Zhao L; Zhang Y; Liu J
    Diabetologia; 2016 Jun; 59(6):1287-96. PubMed ID: 26993634
    [TBL] [Abstract][Full Text] [Related]  

  • 52. OGA inhibition by GlcNAc-selenazoline.
    Kim EJ; Love DC; Darout E; Abdo M; Rempel B; Withers SG; Rablen PR; Hanover JA; Knapp S
    Bioorg Med Chem; 2010 Oct; 18(19):7058-64. PubMed ID: 20822912
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Structural insights into the substrate binding adaptability and specificity of human O-GlcNAcase.
    Li B; Li H; Hu CW; Jiang J
    Nat Commun; 2017 Sep; 8(1):666. PubMed ID: 28939839
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Structure and mechanism of a bacterial beta-glucosaminidase having O-GlcNAcase activity.
    Dennis RJ; Taylor EJ; Macauley MS; Stubbs KA; Turkenburg JP; Hart SJ; Black GN; Vocadlo DJ; Davies GJ
    Nat Struct Mol Biol; 2006 Apr; 13(4):365-71. PubMed ID: 16565725
    [TBL] [Abstract][Full Text] [Related]  

  • 55. PUGNAc treatment leads to an unusual accumulation of free oligosaccharides in CHO cells.
    Mehdy A; Morelle W; Rosnoblet C; Legrand D; Lefebvre T; Duvet S; Foulquier F
    J Biochem; 2012 Apr; 151(4):439-46. PubMed ID: 22337894
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Streptozotocin inhibits O-GlcNAcase via the production of a transition state analog.
    Toleman C; Paterson AJ; Shin R; Kudlow JE
    Biochem Biophys Res Commun; 2006 Feb; 340(2):526-34. PubMed ID: 16376298
    [TBL] [Abstract][Full Text] [Related]  

  • 57. O-GlcNAcase overexpression reverses coronary endothelial cell dysfunction in type 1 diabetic mice.
    Makino A; Dai A; Han Y; Youssef KD; Wang W; Donthamsetty R; Scott BT; Wang H; Dillmann WH
    Am J Physiol Cell Physiol; 2015 Nov; 309(9):C593-9. PubMed ID: 26269457
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Inhibition of O-GlcNAcase by PUGNAc is dependent upon the oxime stereochemistry.
    Perreira M; Kim EJ; Thomas CJ; Hanover JA
    Bioorg Med Chem; 2006 Feb; 14(3):837-46. PubMed ID: 16214344
    [TBL] [Abstract][Full Text] [Related]  

  • 59. O-GlcNAc processing enzymes: catalytic mechanisms, substrate specificity, and enzyme regulation.
    Vocadlo DJ
    Curr Opin Chem Biol; 2012 Dec; 16(5-6):488-97. PubMed ID: 23146438
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Development of GlcNAc-inspired iminocyclitiols as potent and selective N-acetyl-beta-hexosaminidase inhibitors.
    Ho CW; Popat SD; Liu TW; Tsai KC; Ho MJ; Chen WH; Yang AS; Lin CH
    ACS Chem Biol; 2010 May; 5(5):489-97. PubMed ID: 20187655
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.